---
schema_version: "secwatch.filing_event.v1"
accession: "0001798749-23-000062"
form_type: "8-K"
ticker: "JBIO"
cik: "0001798749"
company_name: "Jade Biosciences, Inc."
filed_at: "2023-11-20T23:59:59+00:00"
generated_at: "2026-06-07T23:27:57.374337+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aerovate completes Phase 2b enrollment (202 patients) and enrolls first Phase 3 patient in AV-101 PAH trial

## Summary
- Phase 2b portion of IMPAHCT trial enrolled 202 adult patients with PAH.
- First patient enrolled in Phase 3 portion under adaptive trial design.
- Topline Phase 2b data expected in June 2024.
- Over 120 sites actively recruiting for Phase 3 globally.

## SEC filing metadata
- accession: 0001798749-23-000062
- form_type: 8-K
- ticker: JBIO
- cik: 0001798749
- company_name: Jade Biosciences, Inc.
- filed_at: 2023-11-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1798749/000179874923000062/0001798749-23-000062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1798749/000179874923000062/tmb-20231120x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001798749-23-000062
- JSON: https://secwatch.observer/filing/0001798749-23-000062.json
- Plain text: https://secwatch.observer/filing/0001798749-23-000062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.